Deprecated: Return type of Requests_Cookie_Jar::offsetExists($key) should either be compatible with ArrayAccess::offsetExists(mixed $offset): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Cookie/Jar.php on line 63
Deprecated: Return type of Requests_Cookie_Jar::offsetGet($key) should either be compatible with ArrayAccess::offsetGet(mixed $offset): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Cookie/Jar.php on line 73
Deprecated: Return type of Requests_Cookie_Jar::offsetSet($key, $value) should either be compatible with ArrayAccess::offsetSet(mixed $offset, mixed $value): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Cookie/Jar.php on line 89
Deprecated: Return type of Requests_Cookie_Jar::offsetUnset($key) should either be compatible with ArrayAccess::offsetUnset(mixed $offset): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Cookie/Jar.php on line 102
Deprecated: Return type of Requests_Cookie_Jar::getIterator() should either be compatible with IteratorAggregate::getIterator(): Traversable, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Cookie/Jar.php on line 111
Deprecated: Return type of Requests_Utility_CaseInsensitiveDictionary::offsetExists($key) should either be compatible with ArrayAccess::offsetExists(mixed $offset): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Utility/CaseInsensitiveDictionary.php on line 40
Deprecated: Return type of Requests_Utility_CaseInsensitiveDictionary::offsetGet($key) should either be compatible with ArrayAccess::offsetGet(mixed $offset): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Utility/CaseInsensitiveDictionary.php on line 51
Deprecated: Return type of Requests_Utility_CaseInsensitiveDictionary::offsetSet($key, $value) should either be compatible with ArrayAccess::offsetSet(mixed $offset, mixed $value): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Utility/CaseInsensitiveDictionary.php on line 68
Deprecated: Return type of Requests_Utility_CaseInsensitiveDictionary::offsetUnset($key) should either be compatible with ArrayAccess::offsetUnset(mixed $offset): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Utility/CaseInsensitiveDictionary.php on line 82
Deprecated: Return type of Requests_Utility_CaseInsensitiveDictionary::getIterator() should either be compatible with IteratorAggregate::getIterator(): Traversable, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/internationalworkshopcll2021_861/public/wp-includes/Requests/Utility/CaseInsensitiveDictionary.php on line 91 YIM Agenda – iwCLL 2021
Welcome & Opening Remarks by Tadeusz Robak, MD, PhD; Petra Langerbeins, MD; Bartosz Pula. MD, PhD
8:10 AM (EDT) 14:10 (CEST)
Session 1: Pathogenesis of CLL
Chairs: Dimitar Efremov, MD, PhD; Marek Mraz, PhD; & Elisa ten Hacken, PhD
8:10 AM (EDT)
14:10 (CEST)
10 mins
Small Extracellular Vesicles Derived From CLL Microenvironment Sustain Disease Progression in Vivo by Hampering Antitumor Immunity
(1084065)
Ernesto Gargiulo, MSc
8:20 AM (EDT)
14:20 (CEST)
10 mins
GAB1 – Novel Regulator of Migration Capacity and Tonic AKT Activity in CLL:
Implications for Combinatorial Therapy With BCR Inhibitors
(1084081)
Vaclav Seda, MSc
8:30 AM (EDT)
14:30 (CEST)
10 mins
Effects of SF3B1 K700E Mutation in Chronic Lymphocytic Leukemia and the
Opportunity For Targeted Therapy With SF3B1-Binding Splicing Modulator H3B-8800
(1084295)
Irene Lopez-Oreja, PhD
8:40 AM (EDT)
14:40 (CEST)
10 mins
Role of Ahr and Hif1a in the Suppressive Ability of Tregs During CLL Development
(1083804)
Giulia Maria Pagano, MSc
8:50 AM (EDT)
14:50 (CEST)
10 mins
RPS15 Mutation Impacts B Cell Fate and Drives B Cell Malignancy Through Myc Activation in a Murine Model
(1084599)
Catherine Gutierrez, PhD
9:00 AM (EDT)
15:00 (CEST)
20 mins
Recap, Q&A
9:20 AM (EDT)
15:20 (CEST)
5 mins
Break
9:25 AM (EDT) 15:25 (CEST)
Session 2: Approach Considerations and Treatment Options in CLL
Cell-free DNA (cfDNA)-Based Serial Minimal Residual Disease Assessment
in Patients With Chronic Lymphocytic Leukemia Treated With Time-Limited Obinutuzumab, Acalabrutinib and Venetoclax
(1084129)
Moritz Fürstenau, MD
9:35 AM (EDT)
15:35 (CEST)
10 mins
Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL
(1083568)
Verena Pfister
9:45 AM (EDT)
15:45 (CEST)
10 mins
VENETOCLAX Ramp-Up Strategies for CLL. UK Real-World Multicentre, Retrospective Study
(1084425)
Rocío Figueroa
9:55 AM (EDT)
15:55 (CEST)
10 mins
Utilizing Clinical Features of Progression to Predict Richter’s Syndrome in Patients With CLL Progressing After Ibrutinib
(1084068)
Adam S. Kittai, MD
10:05 AM (EDT)
16:05 (CEST)
10 mins
Evaluation of Immunoglobulin Gene Somatic Hypermutation Status by Next Generation Sequencing Is Superior to Using Sanger Sequencing
(1084095)
Xiaosu Zhao, MD, PhD
10:15 AM (EDT)
16:15 (CEST)
20 mins
Recap, Q&A
10:35 AM (EDT)
16:35 (CEST)
5 mins
Break
10:40 AM (EDT) 16:40 (CEST)
Session 3: Rationally Designed Therapy on the Horizon in CLL
Venetoclax Resistance Mechanisms in CLL Identified By Whole Exome and RNA Sequencing on Longitudinal Patient Samples
(1084402)
Jasneet K. Khalsa, PhD
10:50 AM (EDT)
16:50 (CEST)
10 mins
CD19 Promoter Hypermethylation as Means of Antigen-Negative Escape
to CART-19 Therapy
(1084273)
Lenka Dostalova
11:00 AM (EDT)
17:00 (CEST)
10 mins
A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination With Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
(1082565)
Pallawi Torka, MD
11:10 AM (EDT)
17:10 (CEST)
10 mins
BTK Inhibitors, Irrespective of ITK Inhibition, Downregulate an Immunosuppressive Program in Chronic Lymphocytic Leukemia and Enhance
CD19/CD3-Mediated Cytotoxicity of T-cells
(1084197)
Maissa Mhibik, PhD
11:20 AM (EDT)
17:20 (CEST)
10 mins
Longitudinal Antibody Levels and T-cell Response Following BNT162b mRNA Covid19 Vaccine in Patients With Chronic Lymphocytic Leukemia on Behalf of the Israeli CLL Study Group
(1083588)
Tamar Tadmor, MD
11:30 AM (EDT)
17:30 (CEST)
20 mins
Recap, Q&A
11:50 AM (EDT)
17:50 (CEST)
10 mins
Break
Concurrent Bootcamp Sessions
Basic Biology Investigator Bootcamp Poster Presentations From the Podium and Roundtable Discussion (7 min presentation; 3 min discussion)
Inhibition of the Pentose-Phosphate-Pathway (PPP) Mediates Macrophage Reprogramming and Induces Increased Antibody-Dependent Lymphoma Cell Clearance by Macrophages While Supportive Bystander Function Is Diminished
(1084060)
Anna Beielstein
Single-cell Dynamics of Mitochondrial DNA Mutations and Chromatin Accessibility in Chronic Lymphocytic Leukemia Following Therapeutic Bottlenecks
(1084075)
Livius Penter, MD
IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3K Inhibitor Idelalisib
(1084080)
Veronika Palusova, PhD
Pharmacologic Inhibition of SUMO-Activating Enzyme Potentiates Interferon
Response and T-Cell-Mediated Antitumor Immunity in Chronic Lymphocytic
Leukemia (CLL) and Lymphoma Models
(1083519)
Vi Lam, BS
Targeting Translation by Disrupting the Newly Identified Prohibitin-eIF4F Complex as a Novel Therapeutic Strategy in CLL
(1084070)
Anne Largeot, PhD
12:50 PM (EDT)
18:50 (CEST)
20 mins
Career Development Discussion
1:10 PM (EDT)
19:10 (CEST)
5 mins
Break
Clinical Investigator Bootcamp Poster Presentations From the Podium and Roundtable Discussion (7 min presentation; 3 min discussion)
Chairs: Matthew Davids, MD, MMSc; Talha Munir, MD; & Jennifer Woyach, MD
12:00 PM (EDT)
18:00 (CEST)
50 mins
Outcomes of Patients With Chronic Lymphocytic Leukemia (CLL) Sequentially
Resistant to Both BCL2 and BTK Inhibition
(1083790)
Victor S. Lin, MD
BCL3 Gene Rearrangement at IgH Locus, t(14;19), Identifies an Aggressive Subset of Chronic Lymphocytic Leukemia. An ERIC and Italian Campus CLL Study
(1083625)
Andrea Visentin, MD, PhD
Treatment in the First 24 Months From Diagnosis Predicts Shorter Survival in Binet A Stage Patients With Chronic Lymphocytic Leukemia. A CLL Campus Study
(1083334)
Andrea Visentin, MD, PhD
Optical Genome Mapping: a New Promising Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL)
(1084272)
Anna Puiggros, PhD
Healthcare Team Burden Due To the Utilization of Novel Therapeutics for Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies
(1084593)
Maishara Muquith, B.A.
12:50 PM (EDT)
18:50 (CEST)
20 mins
Career Development Discussion
Matthew Davids, MD, Talha Munir, MD; & Jennifer Woyach, MD
1:10 PM (EDT)
19:10 (CEST)
5 mins
Break
Bootcamp Recap and YIM Award Presentation
1:15 PM (EDT)
19:15 (CEST)
30 mins
Recap of Previous Bootcamp Sessions
TBD
1:45 PM (EDT)
19:45 (CEST)
15 mins
YIM Award and Concluding Remarks
Awards – Petra Langerbeins, MD; Bartosz Pula, MD, PhD